Omeprazole Raises Somatostatin and Motilin in Human Plasma(Pharmacology)
スポンサーリンク
概要
- 論文の詳細を見る
Omeprazole, a proton pump inhibitor (PPI), is widely used in treatment of peptic ulcer, gastro esophageal reflux disease and eradication of Helicobacter pylori. PPIs inhibit final gastric acid secretion stage by blocking H^+/K^+-ATPase. But the mechanism except for gastric antisecretory effect has not understood clearly. So, we examined the effects of omeprazole on the levels of gastrointestinal peptides (somatostatin, motilin, gastrin, vasoactive intestinal peptide (VIP), substance P (SP) and calcitonin gene-related peptide (CGRP)) in plasma from healthy subjects. After a single oral administration of omeprazole, the plasma omeprazole concentration was highest at 120 min. Omeprazole caused a significant increase of plasma somatostatin-immunoreactive substance (IS) levels at 60-240 min and plasma motilin-IS levels at 120-180 min, compared with a placebo group, respectively. The physiological release of plasma gastrin-IS was reduced by the administration of omeprazole at 60 min, but the medicine did not alter the levels of VIP-, CGRP- and SP-IS. These results suggested that the pharmacological effects of omeprazole on regulation of gastrointestinal function are closely related to changes of somatostatin-, motilin- and gastrin-IS levels in human plasma.
- 公益社団法人日本薬学会の論文
- 2005-02-01
著者
-
Sasano H
Tohoku University 21st Century Coe Program 'comprehensive Research And Education Center For Pla
-
Inoue Shin
Department of Internal Medicine, Showa University Dental Hospital
-
ITOH Hiroki
Department of Physics, Faculty of Science, Hokkaido University
-
TAKEYAMA MASAHARU
Department of Anesthesiology and Critical Care Medicine, Kagoshima University School of Medicine
-
Takeyama M
Department Of Clinical Pharmacy Oita University Hospital
-
Inoue S
Department Of Clinical Pharmacy Oita University Hospital
-
Itoh Hiroki
Department Of Cardiology Tokyo Women's Medical University
-
Takeyama Masaharu
Department Of Anesthesiology And Critical Care Medicine Kagoshima University School Of Medicine
-
KATAGIRI Fumihiko
Department of Clinical Pharmacy, Oita University Hospital
-
Takeyama M
Oita Univ. Hospital
-
Inoue Shin
Department Of Clinical Pharmacy Oita University Hospital
-
Inoue S
Fujisawa Technical Serv. Co. Ltd. Osaka Jpn
-
Katagiri Fumihiko
Department Of Clinical Pharmacy Oita University Hospital
-
KATAGIRI Fumihiko
Department of Clinical Biochemistry, Tokyo University of Pharmacy and Life Sciences
関連論文
- Radiation Dose and Radiation Protection for Patients and Physicians During Interventional Procedure
- The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension
- PE-082 Sex Differences of Coronary Plaque Component in Patients with Coronary Spastic Angina : Virtual Histology Study(PE014,Intravascular Imagings (I),Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome : the Ohasama study
- PE-037 A Q312X Mutation in the Hemojuvelin Gene is Associated with Cardiomyopathy due to Juvenile Hemochromatosis(Cardiomyopathy, basic/clinical(03)(M),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
- OE-323 Functional Assay of von Willebrand Factor (VWF) and VWF-cleaving Protease (ADAMTS13) Activity in Acute Myocardial Infarction(Acute myocardial infarction, clinical(pathophysiology)(01)(IHD),Oral Presentation(English),The 72nd Annual Scientific Meeti
- PJ-704 Delays of Hospital Admission from the Onset of Acute Myocardial infarction Induce Poor Prognosis in Women in Kumamoto Prefecture(Preventive medicine/Epidemiology/Education-5, The 71st Annual Scientific Meeting of the Japanese Circulation Society)
- Ten-Year Patency and Factors Causing Restenosis After Endovascular Treatment of Iliac Artery Lesions
- OJ-025 Ten-year Patency of Endovascular Treatment Based on the TransAtlantic Inter-Society Consensus II Classification in Patients with Iliac Artery Lesions(OJ05,Peripheral Circulation/Vascular Disease (Therapy) 1 (H),Oral Presentation (Japanese),The 73rd
- OJ-080 Long-term Results of TransAtlantic Inter-Society Consensus II(TASC-II) Stratification for Percutaneous Peripheral Intervention(PPI) in Patients with Peripheral Arterial Disease(PAD).(Peripheral circulation/Vascular disease(02)(H),Oral Presentation(